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Abstract:  A  series  of  1-substituted  carbazolyl-1,2,3,4-tetrahydro-  and  carbazolyl-3,4-
dihydro--carboline analogs have been synthesized and evaluated for antitumor activity 
against  human  tumor  cells  including  KB,  DLD,  NCI-H661,  Hepa,  and  HepG2/A2  cell 
lines. Among these, compounds 2, 6,  7, and 9 exhibited the most potent and selective 
activity against the tested tumor cells. As for inhibition of topoisomerase II, compounds  
1–14 and 18 showed better activity than etoposide. Among them, compounds 3, 4, 7, 9, and 
10 exhibited potent activity. The structure and activity relationship (SAR) study revealed 
correlation  between  carbon  numbers  of  the  side  chain  and  biological  activities.  The 
molecular complex with DNA for compound 2 was proposed. 
Keywords: carbazolyl-1,2,3,4-tetrahydro--carbolines; carbazolyl-3,4-dihydro--carbolines; 
antitumor agents; structure activity relationship 
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1. Introduction 
Marine invertebrates are rich in -carboline alkaloids [1–3]. These natural -carboline metabolites 
have been found to possess interesting antitumor and antiviral activities [4–6]. Eudistomins [7,8] and 
manzamines [9,10], which were isolated from tunicates and sponges, respectively, are of particular 
interest. The antiviral eudistomines C and E were active against HSV-2, Vaccinia virus and RNA 
viruses [11]. In addition, the novel manzamines exhibited potent antitumor, antibacterial, antifungal 
and anti-HIV activities [12–14]. The major compound, manzamine A, showed most potent activity 
against murine P-388 cells [15]. Our previous paper reported that manzamines A–D and H showed 
significant cytotoxicities against human KB-16, A-549 and HT-29 tumor cells [16]. The -carboline 
and  3,4-dihydro--carboline  moieties  in  manzamines  appear  to  be  essential  for  the  biological  
activity.  In  order  to  investigate  the  structure  and  activity  relationship  (SAR)  and  bioactive  
center  of  manzamine  A,  the  synthesis  of  1-substituted  carbazolyl-1,2,3,4-tetrahydro-  and  
carbazolyl-3,4-dihydro--carboline derivatives were initiated [17]. The limited source of manzamine A 
make this current investigation more urgent and important. The purpose of this study does not include 
all SAR studies of manzamines and -carboline analogs. However, a combination of -carboline and 
various carbazole analogs is addressed. An attempt to realize the possible active center of manzamine 
A and the importance of the alkyl substituents on the nitrogen atom of carbazole ring was conducted. 
Thus, a facile synthetic method by the application of N-alkylation, Duff reaction [18], Pictet-Spengler 
reaction [19,20] and DDQ oxidation [21] succeeded in the production of compounds 1–18. In this 
communication,  we  wish  to  report  the  preparation,  structural  elucidation  and  bioactivities  of  
1-substituted carbazolyl-1,2,3,4-tetrahydro- and carbazolyl-3,4-dihydro--carboline analogs. 
2. Results and Discussion 
2.1. Analog Design and Chemistry 
The basic strategy for the synthesis of the target substances involved molecular modeling and SAR 
studies  of  manzamine  analogs.  To  improve  our  knowledge  of  the  main  structural  requirements  
needed  for  high  antitumor  activity,  we  synthesized  two  new  series  of  1-substituted  
carbazolyl-1,2,3,4-tetrahydro--carboline and carbazolyl-3,4-dihydro--carboline derivatives based on 
the analog design of manzamine A. These new compounds bear an N-alkyl carbazole conjugated with 
a -carboline-like nucleus. The main part of manzamine A illustrated in Figure 1 is similar in both 
shape and size to our target compounds. The distances between N atom on carbazole and N atoms on 
carboline-nucleus are almost the same as those in the main part. With the aim of studying the SAR, we 
focused  on  the  lengh  of  the  N-alkyl  side  chain  on  the  carbazole  ring.  Compounds  19–26  were  
prepared by N-alkylation of carbazole with the appropriate alkyl bromide as depicted in Scheme 1.  
Subsequent  synthesis  of  compounds  27–34  was  achieved  by  Duff  reaction,  which  required 
hexamethylenetetramine/trifloroacetic acid and the appropriate N-alkyl carbazole. Compounds 1, 3, 5, 
7,  9,  11,  13,  15,  and  17  (A  series)  were  furnished  from  tryptamine  and  series  of  N-substituted  
3-carbazolyl carboxyaldehydes (27–34, and N-ethyl-3-carboxyaldehyde, which was purchased from 
Sigma-Aldrich  Co.)  by  application  of  Pictet-Spengler  cyclization.  Subsequent  oxidation  of  
1,2,3,4-tetrahydro--carbolines (A) by DDQ yielded 3,4-dihydro--carboline derivatives (B series: 2, Mar. Drugs 2011, 9  
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4,  6,  8,  10,  12,  14,  16,  18).  The  preparation  and  spectral  data  for  1–34  are  described  in  the 
Experimental Section. 
Figure 1. The main part of manzamine A. 
 
Scheme 1. Preparation of compounds 1–36. 
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2.2. Biological Activity 
Cytotoxicity of new products 1–18 was tested against KB (human mouth epidermoid carcinoma); 
DLD (human colon adenocarcinoma), NCI-H661 (human lung large cell carcinoma) and Hepa (human 
hepatoma), HepG2/A2 (human hepatoma) tumor cells in vitro. The IC50 values of these compounds are 
summarized in Table 1. Table 1 shows that compounds 1–12 exhibited significant and/or selective 
cytotoxic  activities.  Among  them,  compounds  2  and  6  are  most  potent  against  KB  tumor  cells 
selectively. Compound 7 is more potent than 2 against NCI-H661 tumor cells although compound 2 
shows  most  promising  activity  against  all  tumor  cells.  On  the  other  hand,  compounds  14–18  are 
inactive  toward  four  tumor  cells  while  compounds  11–13  exhibit  weak,  marginal  or  no  activity. 
Table 1 also shows that these compounds have selective cytotoxicity against HepG2/A2 tumor cells. 
Compounds 2–4 and 8 are active while others are inactive. In this assay, compound 2 exhibits most 
potent activity against the HepG2/A2 system. 
Table 1. Cytotoxicity of Compounds 1–18 against Human Cancer Cells (IC50, μg/mL) 
a. 
Compound/Cell line  KB  DLD  NCI-H661  Hepa  HepG2/A2 
1  3.47   1.69   1.82   NT 
b  NT 
2  0.71   1.09   0.84   NT  0.60 
3  1.84   1.58   2.14   NT  6.10 
4  2.72   2.16   5.02   NT  5.10 
5  3.00   NT  NT  2.25   NT 
6  0.48   NT  NT  2.67   NT 
7  3.45   3.75   0.22   NT  20.50 
8  >20  1.29   3.39   NT  5.40 
9  2.96   NT  NT  1.12   NT 
10  3.13   NT  NT  4.40  NT 
11  >20  1.57   >20  NT  20.70 
12  9.13   2.55   5.28   NT  30.10 
13  6.36   10.40   13.90   NT  >60 
14  >20  >20  >20  >20  >60 
15  >20  >20  >20  >20  >60 
16  >20  >20  >20  >20  >60 
17  >20  >20  >20  >20  >60 
18  >20  >20  >20  >20  >60 
a The concentration of compound which inhibited 50% (IC50) of the growth of tumor cell lines  
(KB, human mouth epidermoid carcinoma; DLD, human colon adenocarcinoma; NCI-H661, human 
lung  large  cell  carcinoma;  Hepa  and  HepG2/A2,  human  hepatoma);  All  data  estimated  by 
interpolation method; Doxorubicin was used as a positive control (IC50, 0.1 g/mL); 
b Not tested. 
The SAR study revealed that there was not a linear relationship between the carbon number of the 
side  chain  at  N  atom  in  carbazole  and  cytotoxicity.  Nevertheless,  we  observed  that,  in  general, 
elongation of the alkyl chain resulted in a decrease in activity. In fact, compounds 11–18 showed very 
weak or no activity toward HepG2/A2, KB and NCI-H661 cells even though compound 11 was active 
in DLD assay.  Mar. Drugs 2011, 9  
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Inhibition activity of compounds 1–18 was evaluated against human DNA topoisomerases I and II. 
Table 2  indicates  that  compounds  1–14  and  18  are  more  potent  inhibitors  of  human  DNA 
topoisomerase II than etoposide. Among the tested compounds, 3, 4, 7, 9 and 10 were most potent. On 
the other hand, all compounds were inactive or showed mild activity against DNA topoisomerase I. 
Compounds 3, 4, 9 and 10 were 10- to 15-fold more potent against topoisomerase II (compared to 
etoposide) and superior to compounds 1 and 2. On the other hand, compound 18 showed great activity 
while compounds 15–17 did not.  
Compound 7 showed much better activity than that of 2 suggesting that the different degrees of 
activity might be explained by the differences in binding affinity or bioavailability such as drug uptake 
and fate of metabolism. 
Table 2. Inhibition of DNA topoisomerases I and II (IC50, μg/mL) 
a by compounds 1–18. 
Compound  DNA topoisomerase I   DNA topoisomerase II 
1  >100  9.5 
2  >100  8.5 
3  47.0   1.6 
4  >100  2.1 
5  >100  10.0  
6  >100  26.0  
7  89.0   2.7 
8  58.0   22.0  
9  96.0   2.8 
10  67.0   2.7 
11  >100  30.0  
12  >100  29.0  
13  >100  28.0  
14  >100  19.0  
15  >100  >100 
16  >100  >100 
17  >100  >100 
18  >100  5.6 
Camptothecin  17.0   NT 
Etoposide  NT  31.0  
a Each compound was examined with five concentrations at 5, 10, 25, 50 and 100 g/mL; The IC50 
value was measured based on the degree of inhibition at these five concentrations; NT: Not tested. 
2.3. Molecular Modeling 
To rationalize the biological activity results obtained for this novel series of carbazolyl-3,4-dihydro-
-carbolines, we carried out a molecular modeling study of compound 2. The molecular modeling was 
performed  by  making  use  of  two  double  strand  DNA  fragments  (CGCTAGGG)2  and 
(CGCGAATTCGCGG)2. Figure 2 shows the result of d(CGCATGGG)2-compound 2 complex. It was 
found that the binding conformation of this complex was formed by intercalation. Unlike the usual 
planar intercalators, compound 2 inserts into base pairs of DNA in a scissor-like conformation. We 
observed that the carbazole moiety of compound 2 was parallel with the thymidine base. However, the Mar. Drugs 2011, 9  
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conformation of d(CGCGAATTGCG)2-compound 2 complex, as illustrated in Figure 3, was formed 
by minor groove binding.  In this  case, compound  2  interacts  with  DNA by putting the carbazole 
moiety  in  the  minor  groove  leaving  the  -carboline  chromophore  outside.  The  estimated  binding 
energy values  for these two interaction forms  are −16  and −186 kcal/mole, respectively.  In these 
experiments, the occurrence of hydrogen bonding was observed in both conformations and resulted in 
the formation of a stable drug-DNA complex. The hydrogen bonding between the N-9 of -carboline 
and the oxygen atom of C-2 in thymidine had a bonding length 1.86 and 2.02 Ǻ, respectively [22]. 
Figure  2.  Plot  of  the  d(CGCATGGG)2-compound  2  complex.  (a)  Line  plot:  
Three-dimensional structural model of 2 with DNA receptor binding site; (b) Space-filling 
plot: Compound 2, red; DNA duplex, blue. 
Fig. 49B Plot of the d (CGCATGGG)2-Mana-Hox complex.
The three-dimensional structures of  DNA duplexes was obtained from the 
Brookhaven Protein Databank (PDB code: 108d). The 3D structure of Mana-
Hox was constructed as a protonated form and was assigned Gasteiger-Huckel
partial charges using Sybyl 6.5.  The AutoTors module was used to specify two 
rotatable bonds in Mana-Hox for AutoDock.  The grid maps were calculated 
with AutoGrid using a grid-point spacing of 0.3 Å, and 100 x 76 x 76 grid 
points for 108d. 200 independent docking runs were carried out using the 
Lamarckian genetic algorithm (LGA) with a maximum number of 500,000 
energy evaluations and a population of 50 randomly initiated individuals. The 
lowest-energy docked conformations proposed the energetically favorable
binding modes of  Mana-Hox to DNA. a, Line plot; b, space-filling plot. The 
following coloring scheme is used: Mana-Hox, red; DNA duplex, blue; Drug-
DNA hydrogen bond, green.
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Figure  3.  Plot  of  the  d(CGCGAATTGCG)2-compound  2  complex.  (a)  Line  plot:  
Three-dimensional structural model of 2 with DNA receptor binding site; (b) Space-filling 
plot: Compound 2, red; DNA duplex, blue. 
Fig. 50B Plot of the d (CGCGAATTGCG)2- Mana-Hox complex.
The three-dimensional structures of two DNA duplexes were obtained from 
the Brookhaven Protein Databank (PDB code: 264d). The 3D structure of 
Mana-Hox  was constructed as a protonated form and was assigned 
Gasteiger-Huckel partial charges using Sybyl 6.5.  The AutoTors module 
was used to specify two rotatable bonds in Mana-Hox for AutoDock.  The 
grid maps were calculated with AutoGrid using a grid-point spacing of 0.3 Å, 
and 70 x 70 x 110 grid points for 264d.  200 independent docking runs were 
carried out using the Lamarckian genetic algorithm (LGA) with a maximum 
number of 500,000 energy evaluations and a population of 50 randomly 
initiated individuals. The lowest-energy docked conformations proposed the 
energetically favorable binding modes of Mana-Hox to DNA. a, Line plot; b, 
space-filling plot. The following coloring scheme is used: Mana-Hox, red; 
DNA duplex, blue; Drug-DNA hydrogen bond, green.
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3. Experimental Section 
3.1. General Experimental Procedures 
All of melting points were taken on a Buchi mp B-540 apparatus and were uncorrected. UV and IR 
spectra were recorded on Hitachi U-3210 and JASCO A-100 IR spectrophotometers, respectively. 
EIMS spectra were obtained on a MAT 112S-JMS D300 spectrometer, using direct inlet systems. 
HRMS data were taken on a JMX 110 mass spectrometer. 
1H- and 
13C-NMR spectra were recorded on 
a Bruker FT-300 spectrometer. Analytical thin-layer chromatography (TLC) was carried out on Kiesel 
gel GF254 plates and detection was made under UV light. EM Kieselgel 60 (230–400 mesh ASTM) was 
used for column chromatography. 
3.2. Synthesis of Compounds 1, 3, 5, 7, 9, 11, 13, 15, and 17 
To a stirred solution of tryptamine (160 mg, 0.1 mmol), the appropriate substituted aldehyde (27–34, 
and N-ethyl-3-carbazolyl carboxyaldehyde; 0.1 mmol) in acetic acid (30 mL) was heated to 100 ° C. 
The reaction mixture was maintained at 100 °C  for 24 h. After cooling, the reaction mixture was 
neutralized with NH4OH solution and extracted with CHCl3. The CHCl3 layer was evaporated under 
vacuum, and the residue was chromatographed on a Silica gel column (10 g) and eluted with solvent 
mixture of CHCl3/MeOH using the following ratios and volumes (70:1, 50:1, 30:1 and 10:1; each 
30 mL), to afford compounds 1, 3, 5, 7, 9, 11, 13, 15, and 17 with a yield in the range of 80–85%. 
3.2.1. 1-(9′-Ethyl-3′-carbazolyl)-1,2,3,4-tetrahydro--carboline (1)  
Yellow solid; mp 240–242 °C ; UV λmax 249, 269, 296, 332, 346 nm; IR (KBr) νmax 3164, 2973, 
1600, 1471, 1334, 806 cm
−1; 
1H NMR (CDCl3) δ 5.36 (1H, s, H-1), 3.37 (1H, m, H-3a), 3.13 (1H, m, 
H-3b), 2.87 (1H, m, H-4a), 2.97 (1H, m, H-4b), 7.64 (1H, d, overlap, H-5), 7.17 (1H, m, H-6), 7.14 
(1H, m, H-7), 7.11 (1H, d, overlap, H-8), 7.29 (1H, d, overlap, H-1′), 7.36 (1H, d, overlap, H-2′), 8.04 
(1H, s, H-4′), 7.44 (1H, d, overlap, H-5′), 7.52 (1H, m, H-6′), 7.25 (1H, m, H-7′), 8.00 (1H, d, overlap,  
H-8′), 4.37 (2H, q, J = 7.1 Hz, H-1″), 1.45 (3H, t, J = 7.1 Hz, H-2″); 
13C NMR (CDCl3) δC 58.4 (d, C-1), 
43.0 (t, C-3), 43.0 (t, C-4), 110.0 (s, C-4a), 127.6 (s, C-4b), 118.2 (d, C-5), 119.3 (d, C-6), 121.6 (d,  
C-7), 111.1 (d, C-8), 136.1 (s, C-8a), 135.5 (s, C-9a), 108.7 (d, C-1′), 126.5 (d, C-2′), 132.3 (s, C-3′), 
120.7 (d, C-4′), 122.8 (s, C-4′a), 123.1 (s, C-4′b), 108.7 (d, C-5′), 126.0 (d, C-6′), 119.1 (d, C-7′), 120.5 
(d, C-8′), 139.8 (s, C-8′a), 140.4 (s, C-9′a), 37.6 (t, C-1″), 13.9 (q, C-2″); EIMS m/z 365 (100, M
+), 364 
(82), 336 (46), 335 (63), 306 (31), 183 (17), 171 (51), 160 (16), 143 (18), 115 (17), 77 (5); HREIMS 
m/z 365.1890 ([M]
+, calcd. for C25H23N3, 365.1892).  
3.2.2. 1-(9′-Propyl-3′-carbazolyl)-1,2,3,4-tetrahydro--carboline (3)  
Yellow solid; mp 110–112 ° C; UV λmax 269, 296, 332, 346 nm; IR (KBr) νmax 3168, 3050, 2964, 
1598, 1469, 1371, 808 cm
−1; 
1H NMR (CDCl3) δ 5.37 (1H, s, H-1), 3.18 (1H, m, H-3a), 3.43 (1H, m, 
H-3b), 2.85 (1H, m, H-4a), 2.99 (1H, m, H-4b), 7.58 (1H, d, overlap, H-5), 7.19 (1H, m, H-6), 7.17 
(1H, m, H-7), 7.16 (1H, d, overlap, H-8), 7.34 (1H, d, overlap, H-1′), 7.41 (1H, d, overlap, H-2′), 8.02 
(1H, s, H-4′), 7.43 (1H, d, overlap, H-5′), 7.48 (1H, dd, overlap, H-6′), 7.23 (1H, dd, overlap, H-7′), Mar. Drugs 2011, 9  
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7.98 (1H, d, overlap, H-8′), 4.24 (2H, t, J = 7.0 Hz, H-1″), 1.89 (2H, m, H-2″), 0.96 (3H, t, J = 7.3 Hz, 
H-3″);
13C NMR (CDCl3) δC 58.3 (d, C-1), 42.8 (t, C-3), 22.4 (t, C-4), 109.9 (s, C-4a), 127.5 (s, C-4b), 
118.2 (d, C-5), 119.3 (d, C-6), 121.6 (d, C-7), 111.1 (d, C-8), 136.1 (s, C-8a), 135.0 (s, C-9a), 109.7 (d, 
C-1′), 126.4 (d, C-2′), 131.7 (s, C-3′), 120.6 (d, C-4′), 122.6 (s, C-4′a), 122.9 (s, C-4′b), 108.9 (d, C-5′), 
125.9 (d, C-6′), 119.1 (d, C-7′), 120.4 (d, C-8′), 140.4 (s, C-8′a), 140.9 (s, C-9′a), 44.7 (t, C-1″), 22.4 (t,  
C-2″)11.8 (q, C-3″); EIMS m/z 379 (89, M
+), 378 (100, M-1
+),350 (65), 306 (31), 190 (22), 180 (22), 
171 (58), 159 (43), 115 (13), 77 (4).  
3.2.3. 1-(9′-[1″-Methyl]propyl-3′-carbazolyl)-1,2,3,4-tetrahydro--carboline (5)  
Yellow solid; mp 127–130 ° C; UV λmax 222, 297, 332, 346 nm; IR (KBr) νmax 3454, 2969, 2929, 
1458, 1335, 742 cm
−1; 
1H NMR (CDCl3) δH 5.31 (1H, s, H-1), 3.16 (1H, m, H-3a), 3.42 (1H, m, H-3b), 
2.87 (1H, m, H-4a), 2.97 (1H, m, H-4b), 7.64 (1H, d, overlap, H-5), 7.15 (1H, m, H-6), 7.15 (1H, m, 
H-7), 7.15 (1H, d, overlap, H-8), 7.53 (1H, d, overlap, H-1′), 7.33(1H, d, overlap, H-2′), 8.04 (1H, s, 
H-4′), 7.45 (1H, d, overlap, H-5′), 7.45 (1H, dd, overlap, H-6′), 7.21 (1H, dd, overlap, H-7′), 8.02 (1H, 
d, overlap, H-8′), 4.67 (2H, m, H-1″), 1.68 (2H, d, J = 6.9 Hz, H-2″), 2.03 (1H, m, H-3a″), 2.15 (1H, 
m, H-3b″), 0.96 (3H, t, J = 7.3 Hz, H-4″); 
13C NMR (CDCl3) δC 58.3 (d, C-1), 43.0 (t, C-3), 19.1 (t,  
C-4), 110.0 (s, C-4a), 127.5 (s, C-4b), 118.2 (d, C-5), 109.3 (d, C-6), 121.5 (d, C-7), 110.1 (d, C-8), 
135.9 (s, C-8a), 135.1 (s, C-9a), 110.3 (d, C-1′), 126.0 (d, C-2′), 131.6 (s, C-3′), 120.5 (d, C-4′), 122.9 
(s, C-4′a), 123.8 (s, C-4′b), 110.2 (d, C-5′), 125.6 (d, C-6′), 118.7 (d, C-7′), 120.3 (d, C-8′), 140.5 (s,  
C-8′a), 139.7 (s, C-9′a), 53.0 (t, C-1″), 14.1 (t, C-2″), 28.0 (t, C-3″), 11.5 (t, C-4″); EIMS m/z 393 (100, 
M
+), 364 (36), 336 (17), 306 (34), 193 (20), 180 (11), 171 (44), 144 (20), 115 (19), 57 (42).  
3.2.4. 1-(9′-Pentyl-3′-carbazolyl)-1,2,3,4-tetrahydro--carboline (7)  
Yellow solid; mp 129–130 ° C; UV λmax 243, 266, 296, 332, 347 nm; IR (KBr) νmax 3405, 3164, 
3050, 2929, 1600, 1467, 1338, 806 cm
−1; 
1H NMR (CDCl3) δH 5.28 (1H, s, H-1), 3.14 (1H, m, H-3a), 
3.41 (1H, m, H-3b), 2.85 (1H, m, H-4a), 2.99 (1H, m, H-4b), 7.63 (1H, d, overlap, H-5), 7.19 (1H, m, 
H-6), 7.18 (1H, m, H-7), 7.16 (1H, d, overlap, H-8), 7.34 (1H, d, overlap, H-1′), 7.37 (1H, d, overlap, 
H-2′), 8.03 (1H, s, H-4′), 7.42 (1H, d, overlap, H-5′), 7.49 (1H, dd, overlap, H-6′), 7.25 (1H, dd, 
overlap, H-7′), 7.99 (1H, d, overlap, H-8′), 4.27 (2H, t, J = 7.1 Hz, H-1″), 1.91 (2H, m, H-2″), 1.41 
(2H, m, H-3″), 1.41 (2H, m, H-4″), 0.96 (3H, t, J = 7.3 Hz, H-2″); 
13C NMR (CDCl3) δC 58.4 (d,  
C-1), 43.1 (t, C-3), 22.6 (t, C-4), 110.0 (s, C-4a), 127.6 (s, C-4b), 118.2 (d, C-5), 119.3 (d, C-6), 121.6 
(d, C-7), 111.0 (d, C-8), 136.0 (s, C-8a), 135.4 (s, C-9a), 109.0 (d, C-1′), 126.4 (d, C-2′), 132.1 (s,  
C-3′), 120.6 (d, C-4′), 122.6 (s, C-4′a), 123.0 (s, C-4′b), 108.9 (d, C-5′), 125.9 (d, C-6′), 119.0 (d, C-7′), 
120.4 (d, C-8′), 140.3 (s, C-8′a), 140.9 (s, C-9′a), 43.2 (t, C-1″), 28.7 (t, C-2″), 29.4 (t, C-3″), 22.5 (t, 
C-4″), 14.0 (q, C-5″); EIMS m/z 407 (90, M
+), 406 (100, M − H
+), 378 (55), 306 (31), 204 (13), 179 
(19), 171 (46), 159 (27), 115 (15), 55 (8).  
3.2.5. 1-(9′-[3″-Methylbutyl]-3′-carbazolyl)-1,2,3,4-tetrahydro--carboline (9)  
Yellow solid; mp 99–101 ° C; UV λmax 222, 296 nm; IR (KBr) νmax 3404, 3192, 3050, 2922, 1468, 
1331, 742 cm
−1; 
1H NMR (CDCl3) δH 5.34 (1H, s, H-1), 3.18 (1H, m, H-3a), 3.46 (1H, m, H-3b), 2.87 Mar. Drugs 2011, 9  
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(1H, m, H-4a), 3.00 (1H, m, H-4b), 7.64 (1H, d, overlap, H-5), 7.17 (1H, dd, overlap, H-6), 7.15 (1H, 
dd, overlap, H-7), 7.14 (1H, d, overlap, H-8), 7.36 (1H, d, overlap, H-1′), 7.40 (1H, d, overlap, H-2′), 
8.04 (1H, s, H-4′), 7.47 (1H, d, overlap, H-5′), 7.56 (1H, dd, overlap, H-6′), 7.22 (1H, dd, overlap,  
H-7′), 8.01 (1H, d, overlap, H-8′), 4.29 (2H, t, J = 7.2 Hz, H-1″), 1.73 (2H, m, H-2″), 1.73 (2H, m,  
H-3″), 1.02 (2H, d, J = 6.0 Hz, H-4″), 1.02 (3H, d, J = 6.0 Hz, H-5″); 
13C NMR (CDCl3) δC 58.1 (d,  
C-1), 42.6 (t, C-3), 22.3 (t, C-4), 109.7 (s, C-4a), 127.3 (s, C-4b), 117.9 (d, C-5), 119.0 (d, C-6), 121.3 
(d, C-7), 110.8 (d, C-8), 135.8 (s, C-8a), 135.2 (s, C-9a), 108.1 (d, C-1′), 126.2 (d, C-2′), 132.0 (s,  
C-3′), 120.4 (d, C-4′), 122.5 (s, C-4′a), 122.8 (s, C-4′b), 108.6 (d, C-5′), 125.7 (d, C-6′), 118.8 (d, C-7′), 
120.2 (d, C-8′), 140.5 (s, C-8′a), 139.9 (s, C-9′a), 41.2 (t, C-1″), 37.3 (t, C-2″), 25.9 (t, C-3″), 22.4 (t,  
C-4″), 22.4 (q, C-5″); EIMS m/z 407 (90, M
+), 378 (48), 319 (15), 306 (25), 204 (29), 180 (23), 171 
(64), 160 (51), 55 (81), 43 (57).  
3.2.6. 1-(9′-Octyl-3′-carbazolyl)-1,2,3,4-tetrahydro--carboline (11)  
Yellow solid; mp 87–89 ° C; UV λmax 247, 266, 296, 332, 347 nm; IR (KBr) νmax 3160, 3056, 2927, 
1600, 1469, 1332, 806, 742 cm
−1; 
1H NMR (CDCl3) δH 5.32 (1H, s, H-1), 3.18 (1H, m, H-3a), 3.44 (1H, 
m, H-3b), 2.88 (1H, m, H-4a), 2.97 (1H, m, H-4b), 7.64 (1H, d, overlap, H-5), 7.19 (1H, m, H-6), 7.17 
(1H, m, H-7), 7.15 (1H, d, overlap, H-8), 7.33 (1H, d, overlap, H-1′), 7.39 (1H, d, overlap, H-2′), 8.04 
(1H, s, H-4′), 7.47 (1H, d, overlap, H-5′), 7.54 (1H, dd, overlap, H-6′), 7.27 (1H, dd, overlap, H-7′), 
8.01 (1H, d, overlap, H-8′), 4.27 (2H, t, J = 7.0 Hz, H-1″), 1.86 (2H, m, H-2″), 1.26–1.35 (10H, 
overlap, H-3″~H-7″), 0.88 (3H, t, J = 6.7 Hz, H-8″); 
13C NMR (CDCl3) δC 58.4 (d, C-1), 42.9 (t,  
C-3), 22.5 (t, C-4), 110.0 (s, C-4a), 127.6 (s, C-4b), 118.2 (d, C-5), 119.1 (d, C-6), 121.6 (d, C-7), 
111.1 (d, C-8), 136.1 (s, C-8a), 135.3 (s, C-9a), 109.0 (d, C-1′), 126.4 (d, C-2′), 132.1 (s, C-3′), 120.6 
(d, C-4′), 122.6 (s, C-4′a), 123.0 (s, C-4′b), 108.9 (d, C-5′), 125.9 (d, C-6′), 118.7 (d, C-7′), 120.4 (d, 
C-8′), 140.3 (s, C-8′a), 140.9 (s, C-9′a), 43.2 (t, C-1″), 29.1 (t, C-2″), 27.4 (t, C-3″), 29.5 (t, C-4″), 29.3 
(t, C-5″), 31.8 (t, C-6″), 22.7 (t, C-7″), 14.2 (q, C-8″); EIMS m/z 449 (83, M
+), 448 (100, M − H
+), 420 
(57), 405 (7), 319 (20), 306 (25), 225 (9), 180 (17), 171 (37), 160 (15), 57 (11).  
3.2.7. 1-(9′-Decyl-3′-carbazolyl)-1,2,3,4-tetrahydro--carboline (13)  
Yellow solid; mp 102–104 ° C; UV λmax 240, 266, 296, 332, 347 nm; IR (KBr) vmax 3048, 2925, 
1598, 1467, 1332, 806 cm
−1; 
1H NMR (CDCl3) δH 5.37 (1H, s, H-1), 3.18 (1H, m, H-3a), 3.43 (1H, m, 
H-3b), 2.88 (1H, m, H-4a), 2.99 (1H, m, H-4b), 7.55 (1H, d, overlap, H-5), 7.15 (1H, m, H-6), 7.14 
(1H, dd, m), 7.16 (1H, d, overlap, H-8), 7.33 (1H, d, overlap, H-1′), 7.40 (1H, d, overlap, H-2′), 8.02 
(1H, s, H-4′), 7.38 (1H, d, overlap, H-5′), 7.47 (1H, dd, overlap, H-6′), 7.20 (1H, dd, overlap, H-7′), 
8.00 (1H, d, overlap, H-8′), 4.25 (2H, t, J = 7.0 Hz, H-1″), 1.83 (2H, m, H-2″), 1.24–1.32 (14H, 
overlap, H-3″~H-9″), 0.88 (3H, t, J =6.3 Hz, H-10″); 
13C NMR (CDCl3) δC 58.0 (d, C-1), 42.4 (t,  
C-3), 21.6 (t, C-4), 109.8 (s, C-4a), 127.2 (s, C-4b), 118.2 (d, C-5), 119.4 (d, C-6), 121.8 (d, C-7), 
110.9 (d, C-8), 135.9 (s, C-8a), 133.7 (s, C-9a), 108.9 (d, C-1′), 126.4 (d, C-2′), 130.1 (s, C-3′), 120.7 
(d, C-4′), 122.4 (s, C-4′a), 122.9 (s, C-4′b), 108.7 (d, C-5′), 125.9 (d, C-6′), 119.0 (d, C-7′), 120.6 (d, 
C-8′), 140.4 (s, C-8′a), 140.7 (s, C-9′a), 43.1 (t, C-1″), 28.9 (t, C-2″), 27.2 (t, C-3″), 29.2-29.5 (t,  
C-4″~C-7″), 31.8 (t, C-5″), 31.8 (t, C-8″), 22.6 (t, C-9″), 14.0 (q, C-10″); EIMS m/z 477 (87, M
+), 476 
(100, M − H
+), 448 (46), 306 (21), 239 (15), 180 (25), 171 (56), 160 (43), 144 (13), 69 (12), 57 (36).  Mar. Drugs 2011, 9  
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3.2.8. 1-(9′-Hexadecyl-3′-carbazolyl)-1,2,3,4-tetrahydro--carboline (15)  
Yellow  solid;  mp  111–113  ° C;  UV  λmax  240, 270  nm;  IR  (KBr)  νmax  2952,  2923,  1467  cm
−1;  
1H NMR (CDCl3) δH 5.34 (1H, s, H-1), 3.15 (1H, m, H-3a), 3.39 (1H, m, H-3b), 2.86 (1H, m, H-4a), 
3.00 (1H, m, H-4b), 7.60 (1H, d, overlap, H-5), 7.14 (1H, dd, overlap, H-6), 7.16 (1H, dd, overlap, m), 
7.17 (1H, d, overlap, H-8), 7.36 (1H, d, overlap, H-1′), 7.39 (1H, d, overlap, H-2′), 8.01 (1H, s, H-4′), 
7.34 (1H, d, overlap, H-5′), 7.48 (1H, dd, overlap, H-6′), 7.21 (1H, dd, overlap, H-7′), 8.03 (1H, d, 
overlap,  H-8′),  4.24  (2H,  t,  J  =  7.2  Hz,  H-1″),  1.83  (2H,  m,  H-2″),  1.26–1.33  (14H,  overlap,  
H-3″~H-15″), 0.90 (3H, t, J = 6.6 Hz, H-16″); 
13C NMR (CDCl3) δC 58.4 (d, C-1), 43.2 (t, C-3), 22.7 
(t, C-4), 109.9 (s, C-4a), 127.4 (s, C-4b), 118.2 (d, C-5), 119.4 (d, C-6), 121.7 (d, C-7), 110.9 (d, C-8), 
134.9 (s, C-8a), 135.9 (s, C-9a), 109.0 (d, C-1′), 126.3 (d, C-2′), 131.3 (s, C-3′), 120.4 (d, C-4′), 122.5 
(s, C-4′a), 122.9 (s, C-4′b), 108.8 (d, C-5′), 125.8 (d, C-6′), 119.0 (d, C-7′), 120.6 (d, C-8′), 140.8 (s,  
C-8′a), 140.4 (s, C-9′a), 43.2 (t, C-1″), 22.7–31.9 (t, C-4″~C-15″), 14.1 (q, C-16″) ; EIMS m/z 561 (4, 
M
+), 368 (1), 313 (1), 236 (3), 180 (2), 97 (6), 83 (11), 69 (17), 57 (28), 44 (100).  
3.2.9. 1-(9′-Eicosyl-3′-carbazolyl)-1,2,3,4-tetrahydro--carboline (17)  
Yellow amorphous powder; UV λmax 221, 263 nm; IR (KBr) νmax 3048, 2925, 1598, 1467, 1332, 
806 cm
−1; 
1H NMR (CDCl3) δH 5.38 (1H, s, H-1), 3.18 (1H, m, H-3a), 3.41 (1H, m, H-3b), 2.88 (1H, 
m, H-4a), 3.01 (1H, m, H-4b), 7.59 (1H, d, overlap, H-5), 7.14 (1H, dd, overlap, H-6), 7.16 (1H, dd, 
overlap, m), 7.17 (1H, d, overlap, H-8), 7.36 (1H, d, overlap, H-1′), 7.39 (1H, d, overlap, H-2′), 8.01 
(1H, s, H-4′), 7.34 (1H, d, overlap, H-5′), 7.46 (1H, dd, overlap, H-6′), 7.21 (1H, dd, overlap, H-7′), 
8.03 (1H, d, overlap, H-8′), 4.24 (2H, t, J = 7.2 Hz, H-1″), 1.83 (2H, m, H-2″), 1.26–1.33 (14H, overlap, 
H-3″~H-19″), 0.91 (3H, t, J = 6.7 Hz, H-20″); 
13C NMR (CDCl3) δC 57.2 (d, C-1), 40.8 (t, C-3), 20.0 (t, 
C-4), 108.5 (s, C-4a), 127.3 (s, C-4b), 117.9 (d, C-5), 119.1 (d, C-6), 121.9 (d, C-7), 111.0 (d, C-8), 
130.8 (s, C-8a), 136.2 (s, C-9a), 108.8 (d, C-1′), 126.3 (d, C-2′), 131.8 (s, C-3′), 120.2 (d, C-4′), 122.1 
(s, C-4′a), 122.8 (s, C-4′b), 108.7 (d, C-5′), 125.8 (d, C-6′), 118.9 (d, C-7′), 120.8 (d, C-8′), 140.6 (s,  
C-8′a), 140.5 (s, C-9′a), 42.9 (t, C-1″), 22.4-31.6 (t, C-2″~C-19″), 13.7 (q, C-20″); EIMS m/z 617 (4, 
M
+), 588 (1), 179 (6), 171 (26), 160 (43), 144 (4), 91 (4), 71 (15), 69 (10), 57 (59), 43 (100). 
3.3. Synthesis of Compounds 2, 4, 6, 8, 10, 12, 14, 16, and 18 
To a stirred solution of compound A (1, 3, 5, 7, 9, 11, 13, 15, 17, 0.68 mmol) in EtOH (2 mL) and 
CHCl3 (6 mL) at room temperature, 2,3-dichloro-5,6-dicyanobezoquinone (DDQ, 160 mg) was added. 
The reaction mixture was stirred for 30 mins. After concentration, the residue was applied on a prep. 
TLC and developed with CHCl3/MeOH (10:1) to yield a series of B (2, 4, 6, 8, 10, 12, 14, 16, and 18) 
(23–64% yield).  
3.3.1. 1-(9′-Ethyl-3′-carbazolyl)-3,4-dihydro--carboline (2)  
Yellow solid; mp 175–177 ° C; UV λmax 236, 288, 323, 346 nm; IR (KBr) νmax 3164, 2973, 1600, 
1471, 1334, 806 cm
−1; 
1H NMR (CDCl3) δH 3.70 (2H, t, J = 7.5 Hz, H-3), 2.93 (2H, t, J = 7.5 Hz,  
H-4), 7.64 (1H, d, overlap, H-5), 7.19 (1H, m, H-6), 7.25 (1H, m, H-7), 7.43 (1H, d, overlap, H-8), 
7.32 (1H, d, overlap,H-1′), 7.87 (1H, d, overlap, H-2′), 8.52 (1H, s, H-4′), 7.30 (1H, d, overlap, H-5′), Mar. Drugs 2011, 9  
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7.46 (1H, m, H-6′), 7.22 (1H, m, H-7′), 8.01 (1H, d, overlap, H-8′), 4.14 (2H, q, J = 7.0 Hz, H-1″), 1.34 
(3H, t, J = 7.0 Hz, H-2″); 
13C NMR (CDCl3) δC 160.5 (s, C-1), 46.4 (t, C-3), 19.4 (t, C-4), 112.8 (s,  
C-4a), 127.7 (s, C-4b), 120.1 (d, C-5), 120.6 (d, C-6), 125.2 (d, C-7), 112.8 (d, C-8), 138.1 (s, C-8a), 
127.7 (s, C-9a), 108.7 (d, C-1′), 126.8 (d, C-2′), 141.4 (s, C-3′), 121.4 (d, C-4′), 122.9 (s, C-4′a), 123.1 
(s, C-4′b), 108.5 (d, C-5′), 126.1 (d, C-6′), 119.5 (d, C-7′), 121.1 (d, C-8′), 126.1 (s, C-8′a), 140.3 (s,  
C-9′a), 37.4 (t, C-1″), 13.7 (q, C-2″); EIMS m/z 363 (100, M
+), 362 (90), 346 (16), 335 (20), 319 (9), 
306 (10), 174 (15), 160 (19), 77 (4), 55 (11); HREIMS m/z 363.1724 ([M]
+, calcd. for C25H21N3, 
363.1735).  
3.3.2. 1-(9′-Propyl-3′-carbazolyl)-3,4-dihydro--carboline (4)  
Yellow solid; mp 126–128 ° C; UV λmax 239, 288, 323 nm; IR (KBr) νmax 3064, 2929, 1596, 1467, 
1336, 808, 746 cm
−1; 
1H NMR (CDCl3) δH 3.96 (2H, t, J = 8.2 Hz, H-3), 2.98 (2H, t, J = 8.3 Hz, H-4), 
7.64 (1H, d, overlap, H-5), 7.17 (1H, m, H-6), 7.26 (1H, m, H-7), 7.44 (1H, d, overlap, H-8), 7.38 (1H, 
d, overlap, H-1′), 7.92 (1H, d, overlap, H-2′), 8.58 (1H, s, H-4′), 7.34 (1H, d, overlap, H-5′), 7.47 (1H, 
m, H-6′), 7.21 (1H, m, H-7′), 8.09 (1H, d, 7.6, H-8′), 4.21 (2H, t, J = 6.9 Hz, H-1″), 1.88 (2H, m,  
H-2″), 0.95(3H, t, 7.4); 
13C NMR (CDCl3) δH 160.2 (s, C-1), 47.3 (t, C-3), 19.4 (t, C-4), 119.0 (s,  
C-4a), 125.4 (s, C-4b), 120.1 (d, C-5), 120.5 (d, C-6), 125.0 (d, C-7), 112.5 (d, C-8), 137.5 (s, C-8a), 
127.8 (s, C-9a), 109.1 (d, C-1′), 126.5 (d, C-2′), 141.9 (s, C-3′), 120.9 (d, C-4′), 122.8 (s, C-4′a), 123.0 
(s, C-4′b), 109.0 (d, C-5′), 126.3 (d, C-6′), 119.5 (d, C-7′), 120.8 (d, C-8′), 126.2 (s, C-8′a), 141.0 (s,  
C-9′a), 44.7 (t, C-1″), 22.3(t, C-2″), 11.7 (q, C-3″); EIMS m/z 377 (98, M
+), 376 (100, M − H
+), 346 
(55), 319 (15), 306 (15), 205 (14), 180 (8), 174 (47), 159 (16), 115 (11), 77 (9), 57 (21); HREIMS  
m/z 377.1880 ([M]
+, calcd. for C26H23N3, 377.1882).  
3.3.3. 1-(9′-[1″-Methyl]propyl-3′-carbazolyl)-3,4-dihydro--carboline (6)  
Yellow solid;  mp 151–154  ° C;  UV  λmax  237,  288  nm;  IR  (KBr)  νmax  3051,  2921,  1468,  1335, 
743 cm
−1; 
1H NMR (CDCl
3) δH 3.67 (2H, t, J = 8.1 Hz, H-3), 2.88 (2H, t, J = 8.1 Hz, H-4), 7.68 (1H, 
d, overlap, H-5), 7.19 (1H, m, H-6), 7.37 (1H, m, H-7), 7.56 (1H, d, overlap, H-8), 7.43 (1H, d, 
overlap,H-1′), 8.05 (1H, d, overlap, H-2′), 8.83 (1H, s, H-4′), 7.45 (1H, d, overlap, H-5′), 7.34 (1H, m, 
H-6′), 7.08 (1H, m, H-7′), 8.08 (1H, d, 7.6, H-8′), 4.56 (2H, t, J = 6.9 Hz, H-1″), 1.56 (2H, m, H-2″), 
1.95 (3H, m, H-3″), 0.70 (3H, m, H-4″); 
13C NMR (CDCl3) δC 160.2 (s, C-1), 43.0 (t, C-3), 19.4 (t,  
C-4), 113.9 (s, C-4a), 125.8 (s, C-4b), 120.9 (d, C-5), 121.6 (d, C-6), 126.8 (d, C-7), 113.9 (d, C-8), 
140.9 (s, C-8a), 126.2 (s, C-9a), 111.0 (d, C-1′), 127.9 (d, C-2′), 140.8 (s, C-3′), 123.7 (d, C-4′), 123.2 
(s, C-4′a), 123.7 (s, C-4′b), 111.0 (d, C-5′), 127.9 (d, C-6′), 120.5 (d, C-7′), 121.8 (d, C-8′), 124.0 (s,  
C-8′a), 140.1 (s, C-9′a), 53.7 (t, C-1″), 19.1 (q, C-2″), 28.1 (t, C-3″), 11.6 (q, C-4″); EIMS m/z 391 (72, 
M
+), 360 (100), 332 (45), 306 (33), 180 (74), 167 (40), 140 (20), 115 (31), 57 (35), 41 (88); HRESIMS 
m/z 392.2125 ([M + H]
+, calcd. for C27H26N3, 392.2127). 
3.3.4. 1-(9′-Pentyl-3′-carbazolyl)-3,4-dihydro--carboline (8)  
Yellow solid; mp 97–98 ° C; UV λmax 236, 288, 324 nm; IR (KBr) νmax 3064, 2929, 1601, 1467, 
1334, 808 cm
−1; 
1H NMR (CDCl3) δH 3.40 (2H, t, J = 7.0 Hz, H-3), 2.91 (2H, t, J = 7.8 Hz, H-4), 7.62 Mar. Drugs 2011, 9  
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(1H, d, overlap, H-5), 7.21 (1H, m, H-6), 7.34 (1H, m, H-7), 7.57 (1H, d, overlap, H-8), 7.27 (1H, d, 
overlap,H-1′), 7.97 (1H, d, overlap, H-2′), 8.64 (1H, s, H-4′), 7.31 (1H, d, overlap, H-5′), 7.48 (1H, m, 
H-6′), 7.25 (1H, m, H-7′), 8.06 (1H, d, 7.6, H-8′), 3.90 (2H, t, J = 6.9 Hz, H-1″), 1.71 (2H, m, H-2″), 
1.28 (3H, m, H-3″), 1.34 (3H, m, H-4″), 0.84 (t, 6.6, H-5″); 
13C NMR (CDCl3) δC 160.5 (s, C-1), 44.9 
(t, C-3), 19.3 (t, C-4), 119.4 (s, C-4a), 124.2 (s, C-4b), 120.1 (d, C-5), 120.6 (d, C-6), 125.7 (d, C-7), 
113.0 (d, C-8), 138.8 (s, C-8a), 127.2 (s, C-9a), 108.7 (d, C-1′), 127.0 (d, C-2′), 142.0 (s, C-3′), 121.7 
(d, C-4′), 122.6 (s, C-4′a), 123.0 (s, C-4′b), 108.6 (d, C-5′), 126.0 (d, C-6′), 119.4 (d, C-7′), 121.1 (d, 
C-8′), 124.8 (s, C-8′a), 140.5 (s, C-9′a), 42.6 (t, C-1″), 28.3 (t, C-2″), 29.1 (t, C-3″), 22.2 (t, C-4″), 13.8 
(q, C-5″); EIMS m/z 405 (83, M
+), 404 (100, M − H
+), 377 (25), 346 (29), 332 (9), 306 (13), 203 (10), 
174 (55), 159 (25), 57 (16); HREIMS m/z 405.2199 ([M]
+, calcd. for C28H27N3, 405.2205).  
3.3.5. 1-(9′-[3″-Methylbutyl]-3′-carbazolyl)-3,4-dihydro--carboline (10)  
Yellow solid; mp 135–137 ° C; UV λmax 236, 289 nm; IR (KBr) νmax 3068, 2927, 1587, 1465, 1332, 
741 cm
−1; 
1H NMR (CDCl3) δH 3.56 (2H, t, J = 8.0 Hz, H-3), 2.76 (2H, t, J = 8.0 Hz, H-4), 7.41 (1H, 
d, overlap, H-5), 7.16 (1H, m, H-6), 7.41 (1H, m, H-7), 7.79 (1H, d, overlap, H-8), 7.24 (1H, d, 
overlap,H-1′), 8.03 (1H, d, overlap, H-2′), 8.86 (1H, s, H-4′), 7.16 (1H, d, overlap, H-5′), 7.36 (1H, m, 
H-6′), 7.14 (1H, m, H-7′), 8.12 (1H, d, J = 7.6 Hz, H-8′), 3.74 (2H, t, J = 6.9 Hz, H-1″), 1.44 (2H, m, 
H-2″), 1.54 (2H, m, H-3″), 0.90 (6H, d, J = 7.6 Hz, H-4″, 5″); 
13C NMR (CDCl3) δC 160.9 (s, C-1), 
41.2 (t, C-3), 19.3 (t, C-4), 114.3 (s, C-4a), 126.8 (s, C-4b), 120.6 (d, C-5), 121.5 (d, C-6), 126.8 (d,  
C-7), 114.3 (d, C-8), 140.6 (s, C-8a), 126.8 (s, C-9a), 109.3 (d, C-1′), 128.8 (d, C-2′), 143.1 (s, C-3′), 
123.4 (d, C-4′), 121.7 (s, C-4′a), 122.5 (s, C-4′b), 108.9 (d, C-5′), 128.0 (d, C-6′), 120.4 (d, C-7′), 121.6 
(d, C-8′), 124.2 (s, C-8′a), 140.6 (s, C-9′a), 41.2 (t, C-1″), 37.1 (q, C-2″), 26.1 (t, C-3″), 22.4 (q, C-4″, 
5″); EIMS m/z 405 (22, M
+), 346 (13), 332 (3), 180 (2), 174 (10), 160 (5), 83 (7), 69 (12), 55 (20), 44 
(100); HRESIMS m/z 406.2284 ([M + H]
+, calcd. for C28H28N3, 406.2283). 
3.3.6. 1-(9′-Octyl-3′-carbazolyl)-3,4-dihydro--carboline (12)  
Yellow solid; mp 91–92 ° C; UV λmax 226, 287, 324 nm; IR (KBr) νmax 3058, 2927, 1596, 1467, 
1336, 744 cm
−1; 
1H NMR (CDCl3) δH 3.77 (2H, t, J = 8.3 Hz, H-3), 2.88 (2H, t, J = 8.7 Hz, H-4), 7.62 
(1H, d, overlap, H-5), 7.17 (1H, m, H-6), 7.30 (1H, m, H-7), 7.45 (1H, d, overlap, H-8), 7.33 (1H, d, 
overlap,H-1′), 7.87 (1H, d, overlap, H-2′), 8.53 (1H, s, H-4′), 7.36 (1H, d, overlap, H-5′), 7.51 (1H, m, 
H-6′), 7.19 (1H, m, H-7′), 8.03 (1H, d, 7.6, H-8′), 4.08 (2H, t, J = 6.9 Hz, H-1″), 1.76 (2H, m, H-2″), 
1.30 (3H, m, H-3″), 1.27–1.29 (8H, m, H-4″~H-7″), 0.92 (t, 6.1, H-8″); 
13C NMR (CDCl3) δC 160.1 (s, 
C-1), 44.8 (t, C-3), 19.4 (t, C-4), 118.1 (s, C-4a), 125.6 (s, C-4b), 120.0 (d, C-5), 120.3 (d, C-6), 124.5 
(d, C-7), 112.2 (d, C-8), 136.8 (s, C-8a), 128.3 (s, C-9a), 109.0 (d, C-1′), 126.5 (d, C-2′), 141.5 (s,  
C-3′), 120.7 (d, C-4′), 122.9 (s, C-4′a), 122.9 (s, C-4′b), 108.9 (d, C-5′), 125.8 (d, C-6′), 119.3 (d,  
C-7′), 120.4 (d, C-8′), 128.0 (s, C-8′a), 141.0 (s, C-9′a), 43.2 (t, C-1″), 29.0 (t, C-2″), 27.3 (t, C-3″), 
29.4 (t, C-4″), 29.2 (t, C-5″), 31.8 (t, C-6″), 22.6 (t, C-7″), 14.2 (q, C-8″); EIMS m/z 447 (81, M
+), 446 
(100, M − H
+), 432 (6), 419 (20), 404 (8), 362 (10), 346 (29), 319 (15), 174 (67), 160 (9), 69 (23), 57 
(46); HREIMS m/z 447.2673 ([M]
+, calcd. for C31H33N3, 447.2674).  Mar. Drugs 2011, 9  
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3.3.7. 1-(9′-Decyl-3′-carbazolyl)-3,4-dihydro--carboline (14)  
Yellow solid; mp 78–80 ° C; UV λmax 233, 289, 323 nm; IR (KBr) νmax 3058, 2927, 1598, 1467, 
1336, 808 cm
−1; 
1H NMR (CDCl3) δH 3.96 (2H, t, J = 7.9 Hz, H-3), 2.94 (2H, t, J = 8.3 Hz, H-4), 7.67 
(1H, d, overlap, H-5), 7.20 (1H, m, H-6), 7.28 (1H, m, H-7), 7.38 (1H, d, overlap, H-8), 7.43 (1H, d, 
overlap,H-1′), 7.85 (1H, d, overlap, H-2′), 8.47 (1H, s, H-4′), 7.41 (1H, d, overlap, H-5′), 7.50 (1H, m, 
H-6′), 7.22 (1H, m, H-7′), 8.02 (1H, d, 7.7, H-8′), 4.23 (2H, t, J = 7.0 Hz, H-1″), 1.83 (2H, m, H-2″), 
1.28–1.33 (14H, m, H-4″~H-9″), 0.93 (t, 6.3, H-10″); 
13C NMR (CDCl3) δC 159.9 (s, C-1), 48.1 (t,  
C-3), 19.2 (t, C-4), 117.9 (s, C-4a), 125.4 (s, C-4b), 119.8 (d, C-5), 120.1 (d, C-6), 124.3 (d, C-7), 
112.1 (d, C-8), 136.7 (s, C-8a), 128.2 (s, C-9a), 108.8 (d, C-1′), 125.7 (d, C-2′), 141.3 (s, C-3′), 120.6 
(d, C-4′), 122.7 (s, C-4′a), 122.7 (s, C-4′b), 108.7 (d, C-5′), 125.9 (d, C-6′), 119.1 (d, C-7′), 120.3 (d, 
C-8′), 127.8 (s, C-8′a), 140.7 (s, C-9′a), 43.0 (t, C-1″), 28.7 (t, C-2″), 27.1 (t, C-3″), 29.1–29.6 (t,  
C-4″~C-7″), 31.7 (t, C-8″), 22.5 (t, C-9″), 14.0 (q, C-10″); EIMS m/z 475 (39, M
+), 460 (4), 349 (27), 
335  (25),  335  (63),  319  (10),  173  (76),  159  (22),  97  (19),  83  (23),  69  (38),  57  (79);  HREIMS  
m/z 475.2987 ([M]
+, calcd. for C33H37N3, 475.2988). 
3.3.8. 1-(9′-Hexadecyl-3′-carbazolyl)-3,4-dihydro--carboline (16)  
Yellow solid; mp 90–92 ° C; UV λmax 238, 288 nm; IR (KBr) νmax 3060, 2925, 1597, 1468, 1338, 
744 cm
−1; 
1H NMR (CDCl3) δH 3.93 (2H, t, J = 8.1 Hz, H-3), 2.93 (2H, t, J = 8.1 Hz, H-4), 7.64 (1H, 
d, overlap, H-5), 7.26 (1H, m, H-6), 7.32 (1H, m, H-7), 7.52 (1H, d, overlap, H-8), 7.38 (1H, d, 
overlap, H-1′), 7.86 (1H, d, overlap, H-2′), 8.49 (1H, s, H-4′), 7.41 (1H, d, overlap, H-5′), 7.45 (1H, m, 
H-6′), 7.23 (1H, m, H-7′), 8.04 (1H, d, J = 7.6 Hz, H-8′), 4.19 (2H, t, J = 7.2 Hz, H-1″), 1.80 (2H, m, 
H-2″), 1.12–1.46 (26H, m, H-3″~15″), 0.90 (3H, t, J = 6.6 Hz, H-16″); 
13C NMR (CDCl3) δC 160.1 (s, 
C-1), 47.5 (t, C-3), 19.4 (t, C-4), 112.9 (s, C-4a), 125.4 (s, C-4b), 120.0 (d, C-5), 120.4 (d, C-6), 125.4 
(d, C-7), 112.4 (d, C-8), 137.3 (s, C-8a), 127.8 (s, C-9a), 108.9 (d, C-1′), 126.1 (d, C-2′), 141.7 (s,  
C-3′), 120.7 (d, C-4′), 122.7 (s, C-4′a), 122.9 (s, C-4′b), 109.0 (d, C-5′), 126.1 (d, C-6′), 119.4 (d,  
C-7′), 120.4 (d, C-8′), 124.9 (s, C-8′a), 140.7 (s, C-9′a), 43.1 (t, C-1″), 22.6–31.9 (C-2″~15″), 14.1 (q, 
C-16″); EIMS m/z 559 (20, M
+), 532 (3), 418 (2), 346 (20), 180 (6), 174 (30), 83 (5), 69 (11), 57 (41), 44 
(100); HRESIMS m/z 560.4008 ([M + H]
+, calcd. for C39H50N3, 560.4005). 
3.3.9. 1-(9′-Eicosyl-3′-carbazolyl)-3,4-dihydro--carboline (18)  
Yellow solid; mp 91–93 ° C; UV λmax 222, 239, 260, 288 nm; IR (KBr) νmax 3062, 2921, 1465, 
1338, 744 cm
−1; 
1H NMR (CDCl3) δH 3.87 (2H, t, J = 8.0 Hz, H-3), 2.93 (2H, t, J = 8.10 Hz, H-4), 
7.61 (1H, d, overlap, H-5), 7.16 (1H, m, H-6), 7.33 (1H, m, H-7), 7.53 (1H, d, overlap, H-8), 7.29 (1H, 
d, overlap,H-1′), 7.99 (1H, d, overlap, H-2′), 8.70 (1H, s, H-4′), 7.38 (1H, d, overlap, H-5′), 7.44 (1H, 
m, H-6′), 7.18 (1H, m, H-7′), 8.08 (1H, d, J = 7.3 Hz, H-8′), 4.07 (2H, t, J = 7.3 Hz, H-1″), 1.75 (2H, 
m, H-2″), 1.25–1.37 (34H, m, H-3″~19″), 0.88 (3H, t, J = 6.7 Hz, H-20″); 
13C NMR (CDCl3) δC 160.6 
(s,  C-1),  44.8  (t,  C-3),  19.2  (t,  C-4),  113.2  (s,  C-4a),  127.3  (s,  C-4b),  120.3  (d,  C-5),  120.9  (d,  
C-6), 126.4 (d, C-7), 113.2 (d, C-8), 139.2 (s, C-8a), 127.3 (s, C-9a), 109.1 (d, C-1′), 127.3 (d, C-2′), 
142.4 (s, C-3′), 122.1 (d, C-4′), 122.6 (s, C-4′a), 123.0 (s, C-4′b), 109.1 (d, C-5′), 126.4 (d, C-6′), 119.9 
(d, C-7′), 121.1 (d, C-8′), 126.4 (s, C-8′a), 140.8 (s, C-9′a), 43.0 (t, C-1″), 22.6–31.9 (C-2″~19″), 14.1 (q, Mar. Drugs 2011, 9  
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C-20″); EIMS m/z 615 (17, M
+), 588 (4), 364 (20), 246 (14), 174 (15), 121 (35), 91 (41), 71 (45), 69 
(64), 57 (100); HRESIMS m/z 616.4627 ([M + H]
+, calcd. for C43H48N3, 616.4631). 
3.4. Synthesis of Compounds 19–22 
To  a  stirred  solution  of  carbazole  (2.0  g,  1.2  mmol)  and  K2CO3  (1.7  g)  in  acetone  (30  mL),  
1-bromopropane,  1-bromopentane,  1-bromooctane  and  1-bromodecane  were  slowly  added, 
respectively (each 5 mL). The reaction mixture was stirred at 50 ° C for 24 hours. After filtration and 
evaporation of the solvent under vacuum, the residue was chromatographed on a silicagel column  
(60 g) and eluted with n-hexane to afford compounds 19–22 with a yield which varied in a range  
of 23–25%. 
3.4.1. N-Propylcarbazole (19)  
White solid; UV λmax 244, 261, 293, 330, 344 nm; IR (CH2Cl2) νmax 3021, 1596, 1484, 1344, 
721 cm
−1; 
1H NMR (CDCl3) δH 8.16 (1H, d, J = 7.7 Hz, H-2), 7.31 (1H, dd, J = 7.7, 6.8 Hz, H-3), 7.52 
(1H, dd, J = 7.7, 6.8 Hz, H-4), 7.45 (1H, d, J = 7.9 Hz, H-5), 4.32 (2H, t, J = 7.1 Hz, H-1′), 1.97 (2H, 
m, H-2′), 1.03 (3H, t, J = 7.4 Hz, H-3′); 
13C NMR (CDCl3) δC 140.3 (s, C-1), 120.1 (d, C-2), 118.8 (d, 
C-3), 126.5 (d, C-4), 108.9 (d, C-5), 122.6 (s, C-6), 44.1 (t, C-1′), 22.3 (t, C-2′), 11.5 (q, C-3′); EIMS 
m/z 209 (85, M
+), 180 (100), 166 (30), 152 (56), 140 (16), 127 (5), 90 (8), 84 (8), 77 (7), 49 (11). 
3.4.2. N-Pentylcarbazole (20)  
White solid; UV λmax 254, 261, 293, 330, 344 nm; IR (CH2Cl2) νmax 3064, 1596, 1484, 1346, 
721 cm
−1; 
1H NMR (CDCl3) δH 8.14 (1H, d, J = 7.7 Hz, H-2), 7.26 (1H, dd, J = 7.7, 6.8 Hz, H-3), 7.50 
(1H, dd, J = 7.7, 6.8 Hz, H-4), 7.43 (1H, d, J = 7.9 Hz, H-5), 4.33 (2H, t, J = 7.1 Hz, H-1′), 1.94 (2H, 
m, H-2′), 1.38–1.43 (4H, overlap, H-3′, 4′), 0.91 (3H, t, J = 6.8 Hz, H-5′; 
13C NMR (CDCl3) δC 140.4 (s, 
C-1), 120.3 (d, C-2), 118.6 (d, C-3), 125.5 (d, C-4), 108.6 (d, C-5), 122.8 (s, C-6), 43.0 (t, C-1′), 28.6 (t, 
C-2′), 29.4 (t, C-3′), 22.4 (t, C-4′), 13.9 (q, C-5′); EIMS m/z 237 (27, M
+), 180 (100), 166 (7), 152 (19), 
140 (5), 127 (2), 84 (2), 77 (2), 49 (2). 
3.4.3. N-Octylcarbazole (21)  
White solid; UV λmax 264, 263, 330, 344 nm; IR (CH2Cl2) νmax 3040, 1596, 1484, 1346, 748, 
721 cm
−1; 
1H NMR (CDCl3) δH 8.23 (1H, d, J = 7.7 Hz, H-2), 7.33 (1H, dd, J = 7.7, 6.8 Hz, H-3), 7.58 
(1H, dd, J = 7.7, 6.8 Hz, H-4), 7.51 (1H, d, J = 7.9 Hz, H-5), 4.37 (2H, t, J = 7.2 Hz, H-1′), 1.97 (2H, 
m, H-2′), 1.37–1.44 (10H, overlap, H-3′~7′), 1.01 (3H, t, J = 6.2 Hz, H-8′; 
13C NMR (CDCl3) δC 140.6 
(s, C-1), 120.5 (d, C-2), 118.8 (d, C-3), 125.7 (d, C-4), 108.8 (d, C-5), 123.0 (s, C-6), 43.2 (t, C-1′), 
29.1 (t, C-2′), 27.4 (t, C-3′), 29.5 (t, C-4′), 29.3 (t, C-5′), 31.9 (t, C-6′), 22.8 (t, C-7′), 14.2 (q, C-8′); 
EIMS m/z 279 (84, M
+), 180 (100), 166 (17), 152 (31), 140 (7), 81 (8), 77 (4), 69 (29), 55 (33). 
3.4.4. N-Decylcarbazole (22)  
White solid; UV λmax 263, 330, 344 nm; IR (CH2Cl2) νmax 2925, 2852, 1484, 1342, 748, 721 cm
−1; 
1H NMR (CDCl3) δH 7.96 (1H, d, J = 7.7 Hz, H-2), 7.09 (1H, dd, J = 7.7, 6.9 Hz, H-3), 7.34 (1H, dd,  Mar. Drugs 2011, 9  
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J = 7.7, 6.9 Hz, H-4), 7.24 (1H, d, J = 8.0 Hz, H-5), 4.12 (2H, t, J = 7.2 Hz, H-1′), 1.71 (2H, m, H-2′), 
1.11–1.19 (14H, overlap, H-3′~9′), 0.76 (3H, t, J = 6.4 Hz, H-10′; 
13C NMR (CDCl3) δC 140.3 (s, C-1), 
120.2 (d, C-2), 118.6 (d, C-3), 125.4 (d, C-4), 108.5 (d, C-5), 122.8 (s, C-6), 42.9 (t, C-1′), 28.8 (t,  
C-2′), 27.2 (t, C-3′), 29.2-29.5 (t, C-4′~7′), 31.8 (t, C-8′), 22.6 (t, C-9′), 14.0 (q, C-10′); EIMS m/z 307 
(84, M+), 194 (7), 180 (100), 166 (14), 152 (22), 140 (5), 81 (5), 69 (23), 55 (32). 
3.5. Synthesis of Compounds 23–26 
To  a  stirred  solution  of  carbazole  (1.0  g,  0.6  mmol)  and  KOH  (0.5  g)  in  EtOH  (20  mL),  
1-bromo-3-methylbuane, 2-bromopentane, 1-bromohexadecane, 1-bromoeicosane were slowly added, 
respectively (each 1 mL or 1 g). The reaction mixture was stirred at 50 ° C for 24 h. After filtration and 
evaporation of the solvent under vacuum, the residue was chromatographed on a silica gel column  
(30 g) and eluted with n-hexane to afford compounds 23–26 with a yield which varied in a range  
of 50–75%. 
3.5.1. N-3′-Methylbutylcarbazole (23)  
White solid; UV λmax 221, 294, 331, 345 nm; IR (CH2Cl2) νmax 3053, 2956, 1452, 748, 721 cm
−1;  
1H NMR (CDCl3) δH 8.14 (1H, d, J = 7.7 Hz, H-2), 7.26 (1H, dd, J = 7.7, 7.0 Hz, H-3), 7.49 (1H, dd,  
J = 7.9, 7.0 Hz, H-4), 7.43 (1H, d, J = 7.9 Hz, H-5), 4.34 (2H, t, J = 7.4 Hz, H-1′), 1.77 (4H, m, H-2′, 3′), 
1.06 (4H, d, J = 6.2 Hz, H-4′, 5′); 
13C NMR (CDCl3) δC 140.3 (s, C-1), 120.3 (d, C-2), 118.7 (d, C-3), 
125.5 (d, C-4), 108.5 (d, C-5), 122.9 (s, C-6), 41.3 (t, C-1′), 26.1 (t, C-2′), 37.5 (d, C-3′), 22.6 (q, C-4′), 
22.6 (q, C-5′); EIMS m/z 237 (94, M
+), 180 (100), 166 (20), 152 (39), 140 (15), 127 (4), 69 (5), 41 (69). 
3.5.2. N-1′-Methylpropylcarbazole (24)  
White solid; UV λmax 221, 294, 330, 344 nm; IR (CH2Cl2) νmax 2962, 1454, 748, 721 cm
−1; 
1H NMR 
(CDCl3) δH 8.19 (1H, d, J = 7.7 Hz, H-2), 7.29 (1H, dd, J = 7.7, 6.9 Hz, H-3), 7.50 (1H, dd, J = 8.0, 6.9 
Hz, H-4), 7.58 (1H, d, J = 8.0 Hz, H-5), 4.74 (2H, m, H-1′), 1.74 (2H, d, J = 7.0 Hz, H-2′), 2.07, (2H, 
m, H-3′), 0.86 (3H, t, J = 7.4 Hz, H-4′); 
13C NMR (CDCl
3) δC 139.9 (s, C-1), 120.2 (d, C-2), 118.5 (d, 
C-3),  125.3  (d,  C-4),  110.0  (d,  C-5),  123.2  (s,  C-6),  52.8  (d,  C-1′),  19.0  (q,  C-2′),  27.9  (t,  
C-3′), 11.4 (q, C-4′); EIMS m/z 223 (36, M
+), 194 (100), 180 (4), 166 (36), 152 (6), 140 (21), 115 (7), 
57 (13), 49 (8). 
3.5.3. N-Hexadecylcarbazole (25)  
White solid; UV λmax 229, 236, 261, 293 nm; IR (CH2Cl2) νmax 3049, 2943, 1452, 746, 719 cm
−1;  
1H NMR (CDCl3) δH 8.11 (1H, d, J = 7.8 Hz, H-2), 7.24 (1H, dd, J = 7.8, 6.9 Hz, H-3), 7.47 (1H, dd,  
J = 8.0, 6.9 Hz, H-4), 7.42 (1H, d, J = 8.0 Hz, H-5), 4.31 (2H, t, J = 7.2 Hz, H-1′), 1.88 (2H, m, H-2′), 
1.25-1.27 (26H, overlap, H-3′~15′), 0.89 (3H, t, J = 6.3 Hz, H-16′); 
13C NMR (CDCl3) δC 140.2 (s,  
C-1), 120.3 (d, C-2), 118.6 (d, C-3), 125.6 (d, C-4), 108.7 (d, C-5), 122.8 (s, C-6), 43.2 (t, C-1′),  
22.8–32.0 (t, C-2′~15′), 14.2 (q, C-16′); EIMS m/z 391 (82, M
+), 194 (7), 180 (100), 167 (9), 152 (10), 
97 (11), 83 (18), 69 (30), 57 (51), 43 (68). Mar. Drugs 2011, 9  
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3.5.4. N-Eicosylcarbazole (26)  
White solid; UV λmax 333, 346 nm; IR (CH2Cl2) νmax 3050, 2956, 1450, 746, 719 cm
−1; 
1H NMR 
(CDCl3) δH 8.25 (1H, d, J = 7.7 Hz, H-2), 7.37 (1H, t, J = 7.4 Hz, H-3), 7.60 (1H, t, J = 7.4 Hz, H-4), 
7.52 (1H, d, J = 8.5 Hz, H-5), 4.38 (2H, t, J = 7.2 Hz, H-1′), 1.98 (2H, m, H-2′), 1.40-1.44 (34H, 
overlap, H-3′~19′), 1.07 (3H, t, J = 6.4 Hz, H-16′); 
13C NMR (CDCl3) δC 140.4 (s, C-1), 120.3 (d,  
C-2),  118.7  (d,  C-3),  125.5  (d,  C-4),  108.6  (d,  C-5),  122.9  (s,  C-6),  43.0  (t,  C-1′),  22.7-32.0  (t,  
C-2′~19′), 14.1 (q, C-20′); EIMS m/z 447 (69, M
+), 194 (5), 180 (100), 167 (8), 152 (7), 97 (3), 83 (5), 
69 (9), 57 (33), 43 (60). 
3.6. Synthesis of Compounds 27–30  
To a stirred solution of N-propylcarbazole (19, 620 mg, 2.9 mmol), N-pentylcarbazole (20, 680 mg, 
2.8  mmol),  N-octylcarbazole  (21,  1  g,  3.5  mmol),  or  N-decylcarbazole  (22,  1  g,  3.2  mmol),  with 
hexamethylenetetramine (420–500 mg, 3–3.5 mmol) in tetrahydrofuran (3–10 mL), trifluroacetic acid 
(1–3.5 mL) was slowly added. The reaction mixtures were refluxed at 80 ° C for 3.5 h. After cooling, the 
solution was partitioned between H2O and CHCl3. The CHCl3-soluble layer was evaporated under 
vacuum,  the  residue  was  chromatographed  on  a  silica  gel  column  (10  g)  and  eluted  with  
N-hexane/CHCl3 mixture with increasing polarity to yield compounds 27–30 with a yield 30–34%.  
3.6.1. N-Propyl-3-carbazolyl Carboxyaldehyde (27)  
White solid; UV λmax 234, 271, 329 nm; IR (CH2Cl2) νmax 2964, 2875, 1685, 1592, 1469, 1349, 
1338, 806 cm
-1; 
1H NMR (CDCl3) δH 7.45 (1H, d, J = 8.4 Hz, H-1), 7.98 (1H, d, J = 8.5 Hz, H-2), 8.60 
(1H, s, H-4), 7.47 (1H, d, J = 6.2 Hz, H-5), 7.53 (1H, dd, J = 7.1, 6.2 Hz, H-6), 7.33 (1H, dd, J = 7.7, 
7.1 Hz, H-7), 8.15 (1H, d, J = 7.7 Hz, H-8), 10.09 (s, CHO), 4.29 (2H, t, J = 7.1 Hz, H-1′), 1.93 (2H, 
m, H-2′), 0.98 (3H, t, J = 7.4 Hz, H-3′); 
13C NMR (CDCl3) δC 109.0 (d, C-1), 127.2 (d, C-2), 128.5 (s, 
C-3), 124.0 (d, C-4), 123.1 (s, C-4a), 123.0 (s, C-4b), 109.5 (d, C-5), 126.7 (d, C-6), 120.3 (d, C-7), 
120.7 (d, C-8), 141.3 (s, C-8a), 144.2 (s, C-9a), 191.8 (d, CHO), 44.9 (t, C-1′), 22.3 (t, C-2′), 11.8 (q, 
C-3′); EIMS m/z 237 (84, M
+), 208 (100), 180 (24), 166 (12), 152 (21), 139 (7), 84 (7), 77 (3), 69 (5), 
49 (15). 
3.6.2. N-Pentyl-3-carbazolyl Carboxyaldehyde (28)  
White solid; UV λmax 234, 271, 329 nm; IR (CH2Cl2) νmax 2954, 2929, 1685, 1592, 1467, 1349, 
1326, 748 cm
−1; 
1H NMR (CDCl3) δH 7.47 (1H, d, J = 8.4 Hz, H-1), 8.01 (1H, d, J = 8.5 Hz, H-2), 8.61 
(1H, s, H-4), 7.50 (1H, d, J = 6.0 Hz, H-5), 7.55 (1H, dd, J = 7.0, 6.0 Hz, H-6), 7.33 (1H, dd, J = 7.6, 
7.0 Hz, H-7), 8.16 (1H, d, J = 7.6 Hz, H-8), 10.10 (s, CHO), 4.34 (2H, t, J = 7.3 Hz, H-1′), 1.89 (2H, m, 
H-2′), 1.26–1.37 (2H, m, H-3′), 1.26–1.37 (2H, m, H-4′), 0.98 (3H, t, J = 6.3 Hz, H-5′); 
13C NMR 
(CDCl3) δC 109.3 (d, C-1), 127.1 (d, C-2), 128.4 (s, C-3), 123.9 (d, C-4), 122.9 (s, C-4a), 123.0 (s,  
C-4b), 108.9 (d, C-5), 126.6 (d, C-6), 120.2 (d, C-7), 120.7 (d, C-8), 141.1 (s, C-8a), 144.0 (s, C-9a), 
191.7 (d, CHO), 43.3 (t, C-1′), 28.5 (t, C-2′), 29.3 (t, C-3′), 22.3 (t, C-4′), 13.8 (q, C-5′); EIMS m/z 266 
(99, M + 1
+), 265 (76, M
+), 208 (34), 180 (14), 167 (12), 154 (100), 136 (73), 107 (25), 89 (21), 77 
(25), 55 (26). Mar. Drugs 2011, 9  
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3.6.3. N-Octyl-3-carbazolyl Carboxyaldehyde (29)  
White solid; UV λmax 234, 276, 290, 331 nm; IR (CH2Cl2) νmax 2950, 2927, 2875, 1687, 1592, 1467, 
1351, 1338 cm
−1; 
1H NMR (CDCl3) δH 7.46 (1H, d, J = 8.4 Hz, H-1), 8.02 (1H, d, J = 8.5 Hz, H-2), 
8.62 (1H, s, H-4), 7.48 (1H, d, J = 7.7 Hz, H-5), 7.54 (1H, dd, J = 7.1, 7.7 Hz, H-6), 7.33 (1H, dd,  
J = 7.6, 7.1 Hz, H-7), 8.16 (1H, d, J = 7.6 Hz, H-8), 10.10 (s, CHO), 4.34 (2H, t, J = 7.1 Hz, H-1′), 
1.88  (2H,  m,  H-2′),  1.25-1.36  (2H,  m,  H-3′),  1.25–1.30  (2H,  m,  H-4′),  1.26–1.36  (2H,  m,  H-5′),  
1.25–1.36 (2H, m, H-6′), 1.25–1.36 (2H, m, H-7′), 0.86 (3H, t, J = 7.4 Hz, H-8′); 
13C NMR (CDCl3) δC 
109.0 (d, C-1), 127.2 (d, C-2), 128.5 (s, C-3), 124.0 (d, C-4), 123.1 (s, C-4a), 123.0 (s, C-4b), 109.4 (d, 
C-5), 126.7 (d, C-6), 120.3 (d, C-7), 120.8 (d, C-8), 141.2 (s, C-8a), 144.1 (s, C-9a), 191.8 (d, CHO), 
43.5 (t, C-1′), 29.1 (t, C-2′), 27.3 (t, C-3′), 29.7 (t, C-4′), 29.3 (t, C-5′), 31.8 (t, C-6′), 22.6 (t, C-7′), 
14.1 (q, C-8′); EIMS m/z 307 (71, M
+), 242 (12), 224 (56), 208 (100), 180 (34), 166 (13), 152 (25), 
139 (6), 77 (4), 69 (26), 55 (43). 
3.6.4. N-Decyl-3-carbazolyl Carboxyaldehyde (30)  
White solid; UV λmax 234, 274, 290, 331 nm; IR (CH2Cl2) νmax 2952, 2925, 1687, 1592, 1467, 1351, 
1338, 806 cm
−1; 
1H NMR (CDCl3) δH 7.47 (1H, d, J = 8.4 Hz, H-1), 8.02 (1H, d, J = 8.4 Hz, H-2), 8.62 
(1H, s, H-4), 7.49 (1H, d, J = 7.5 Hz, H-5), 7.54 (1H, dd, J = 6.9, 7.5 Hz, H-6), 7.35 (1H, dd, J = 7.6, 
6.9 Hz, H-7), 8.17 (1H, d, J = 7.6 Hz, H-8), 10.11 (s, CHO), 4.31 (2H, t, J = 7.2 Hz, H-1′), 1.91 (2H, m, 
H-2′), 1.26–1.37 (2H, m, H-3′), 1.26–1.37 (2H, m, H-4′), 1.26–1.37 (2H, m, H-5′), 1.26–1.37 (2H, m,  
H-6′),  1.26–1.37  (2H,  m,  H-7′),  1.26–1.37  (2H,  m,  H-8′),  1.26–1.37  (2H,  m,  H-9′),  0.89  (3H,  t,  
J = 6.2 Hz, H-10′); 
13C NMR (CDCl3) δC 109.0 (d, C-1), 127.2 (d, C-2), 128.5 (s, C-3), 124.0 (d, C-4), 
123.1 (s, C-4a), 123.0 (s, C-4b), 109.4 (d, C-5), 126.7 (d, C-6), 120.3 (d, C-7), 120.8 (d, C-8), 141.2 (s,  
C-8a), 144.1 (s, C-9a), 191.8 (d, CHO), 43.5 (t, C-1′), 28.9 (t, C-2′), 27.3 (t, C-3′), 29.3-29.5 (t, C-4′), 
29.3-29.5 (t, C-5′), 29.3-29.5 (t, C-6′), 29.3–29.5 (t, C-7′), 31.9 (t, C-8′). 22.7 (t, C-9′), 14.1 (q, C-10′); 
EIMS m/z 335 (67, M
+), 224 (7), 208 (100), 194 (5), 180 (23), 166 (7), 77 (1), 69 (9), 55 (3), 43 (43). 
3.7. Synthesis of Compounds 31–34 
Trifluroacetic acid (2.5–5 mL) was slowly added to a stirred solution of N-3′-methylbutylcarbazole 
(23, 950 mg, 5.1 mmol), N-1′-methylpropylcarbazole (24, 950 mg, 4.3 mmol), N-hexadecylcarbazole 
(25, 1.2 g, 3.0 mmol), or N-decylcarbazole (26, 950 mg, 2.1 mmol), with hexamethylenetetramine  
(810 mg–1 g, 5.1–6.3 mmol) in tetrahydrofuran (2.5–5 mL). The reaction mixtures were refluxed at 
80 ° C  for  3.5  hours.  After  cooling,  the  solution  was  partitioned  between  H2O  and  CHCl3.  
The CHCl3-soluble layer was evaporated under vacuum, the residue was chromatographed on a silica 
gel  column  (10  g)  and  eluted  with  N-hexane/CHCl3  mixture  with  increasing  polarity  to  yield 
compounds 31–34 with a yield of 21–25%.  
3.7.1. N-3′-Methylbutyl-3-carbazolyl Carboxyaldehyde (31)  
White  solid;  UV  λmax  232,  271,  294,  331  nm;  IR  (CH2Cl2)  νmax  2956,  1685,  1593,  748  cm
−1;  
1H NMR (CDCl3) δH 7.45 (1H, d, J = 8.3 Hz, H-1), 8.01 (1H, d, J = 8.5 Hz, H-2), 8.60 (1H, s, H-4), 
7.45 (1H, d, J = 8.0 Hz, H-5), 7.54 (1H, dd, J = 8.0Hz, H-6), 7.33 (1H, dd, J = 7.2, 7.7 Hz, H-7), 8.15 Mar. Drugs 2011, 9  
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(1H, d, J = 7.7 Hz, H-8), 10.10 (s, CHO), 4.33 (2H, t, J = 6.6 Hz, H-1′), 1.76 (2H, m, H-2′), 1.76 (3H, 
m, H-3′), 1.04 (2H, d, J = 5.0 Hz, H-4′), 1.04 (2H, d, J = 5.0 Hz, H-3′); 
13C NMR (CDCl3) δC 108.8 (d,  
C-1), 127.1 (d, C-2), 128.5 (s, C-3), 123.9 (d, C-4), 123.0 (s, C-4a), 123.1 (s, C-4b), 109.2 (d, C-5), 
126.7 (d, C-6), 120.3 (d, C-7), 120.7 (d, C-8), 141.0 (s, C-8a), 143.9 (s, C-9a), 191.7 (d, CHO), 41.7 (t, 
C-1′), 26.1 (t, C-2′), 37.4 (d, C-3′), 22.5 (q, C-4′), 22.5 (q, C-5′); EIMS m/z 265 (81, M
+), 208 (100), 
195 (9), 180 (34), 166 (16), 152 (33), 139 (9), 84 (8), 69 (10), 41 (33). 
3.7.2. N-1′-Methylpropyl-3-carbazolyl Carboxyaldehyde (32) 
White solid; UV λmax 232, 276, 294, 332 nm; IR (CH2Cl2) νmax 2962, 1685, 1684, 1591, 1489, 1338, 
748 cm
−1; 
1H NMR (CDCl3) δH 7.58 (1H, d, J = 8.7 Hz, H-1), 8.00 (1H, d, J = 8.7 Hz, H-2), 8.64 (1H, s, 
H-4), 7.58 (1H, d, J = 8.2 Hz, H-5), 7.51 (1H, dd, J = 8.2, 7.1 Hz, H-6), 7.32 (1H, dd, J = 7.61, 7.7 Hz, 
H-7), 8.18 (1H, d, J = 7.7 Hz, H-8), 10.10 (s, CHO), 4.73 (2H, m, H-1′), 1.71 (2H, d, J = 7.0 Hz,  
H-2′), 2.50–2.30 (2H, m, H-3′), 0.80 (2H, m, H-4′); 
13C NMR (CDCl3) δC 110.1 (d, C-1), 126.8 (d,  
C-2), 128.2 (s, C-3), 123.7 (d, C-4), 123.4 (s, C-4a), 123.4 (s, C-4b), 110.8 (d, C-5), 126.4 (d, C-6), 
120.0 (d, C-7), 120.6 (d, C-8), 141.0 (s, C-8a), 144.0 (s, C-9a), 191.6 (d, CHO), 53.5 (d, C-1′), 19.1 (q, 
C-2′), 28.0 (t, C-3′), 11.4 (q, C-4′); EIMS m/z 251 (80, M
+), 222 (100), 194 (78), 180 (5), 166 (54), 152 
(10), 139 (31), 113 (6), 69 (11), 57 (29). 
3.7.3. N-Hexadecyl-3-carbazolyl Carboxyaldehyde (33) 
White solid; UV λmax 234, 294, 332 nm; IR (CH2Cl2) νmax 2920, 1689, 1593, 1462, 1352, 806 cm
−1;  
1H NMR (CDCl3) δH 7.48 (1H, d, J = 8.5 Hz, H-1), 8.01 (1H, d, J = 8.5 Hz, H-2), 8.62 (1H, s, H-4), 7.46 
(1H, d, J = 8.1 Hz, H-5), 7.54 (1H, dd, J = 8.1, 7.1 Hz, H-6), 7.33 (1H, dd, J = 7.1, 7.7 Hz, H-7), 8.17 
(1H, d, J = 7.7 Hz, H-8), 10.10 (s, CHO), 4.34 (2H, t, J = 7.2 Hz, H-1′), 1.90 (2H, m, H-2′), 1.24–1.26 
(2H, m, H-3′), 1.24–1.26 (2H, m, H-4′), 1.24–1.26 (2H, m, H-5′), 1.24–1.26 (2H, m, H-6′~15′), 0.89 
(2H, m, H-16′); 
13C NMR (CDCl3) δC 109.0 (d, C-1), 127.2 (d, C-2), 128.6 (s, C-3), 126.8 (d, C-4), 
123.1 (s, C-4a), 123.1 (s, C-4b), 109.5 (d, C-5), 126.8 (d, C-6), 120.3 (d, C-7), 120.8 (d, C-8), 141.2 (s, 
C-8a),  144.1  (s,  C-9a),  191.8  (d,  CHO),  43.5  (t,  C-1′),  22.8-32.0  (m,  C-2′),  22.8–32.0  (m,  C-3′),  
22.8–32.0 (m, C-4′), 22.8-32.0 (m, C-5′), 22.8–32.0 (m, C-6′~15′), 14.2 (q, C-16′); EIMS m/z 419 (53, 
M
+), 208 (100), 194 (4), 180 (20), 166 (6), 152 (6), 83 (2), 69 (7), 57 (31), 43 (91). 
3.7.4. N-Eicosyl-3-carbazolyl Carboxyaldehyde (34) 
White solid; UV λmax 235, 275, 290 nm; IR (CH2Cl2) νmax 2918, 1687, 752 cm
−1; 
1H NMR (CDCl3) 
δH 7.46 (1H, d, J = 8.5 Hz, H-1), 8.01 (1H, d, J = 8.5 Hz, H-2), 8.60 (1H, s, H-4), 7.46 (1H, d,  
J = 8.1 Hz, H-5), 7.54 (1H, dd, J = 8.1, 7.1 Hz, H-6), 7.33 (1H, dd, J = 7.1, 7.7 Hz, H-7), 8.17 (1H, d,  
J = 7.7 Hz, H-8), 10.10 (s, CHO), 4.31 (2H, t, J = 7.2 Hz, H-1′), 1.89 (2H, m, H-2′), 1.25–1.27 (2H, m, 
H-3′), 1.25–1.27 (2H, m, H-4′), 1.25–1.27 (2H, m, H-5′), 1.25–1.27 (2H, m, H-6′~15′), 1.25–1.27 (2H, 
m, H-16′), 1.25–1.27 (2H, m, H-17′~19′), 0.90 (3H, t, J = 7.7 Hz, H-20′); 
13C NMR (CDCl3) δC 108.9 
(d, C-1), 127.1 (d, C-2), 128.8 (s, C-3), 123.9 (d, C-4), 123.0 (s, C-4a), 123.0 (s, C-4b), 109.3 (d, C-5), 
126.6 (d, C-6), 120.2 (d, C-7), 120.7 (d, C-8), 140.6 (s, C-8a), 143.6 (s, C-9a), 191.6 (d, CHO), 43.4 (t, 
C-1′), 22.7–31.9 (t, C-2′), 22.7–31.9 (t, C-3′),  22.7–31.9 (t,  C-4′),  22.7–31.9  (t,  C-5′),  22.7–31.9  (t,  Mar. Drugs 2011, 9  
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C-6′~15′), 22.7–31.9 (t, C-16′), 22.7–31.9 (t, C-17′~19′), 14.1 (q, C-20′).; EIMS m/z 475 (71, M
+), 208 
(100), 194 (5), 180 (28), 166 (7), 152 (8), 83 (7), 69 (17), 57 (57), 43 (88) 
3.8. Cytotoxicity Assay 
The cytotoxic activities of compounds against KB (human mouth epidermoid carcinoma), DLD (human 
colon adenocarcinoma), NCI-H661 (human lung large cell carcinoma), Hepa (human hepatoma), and 
HepG2/A2 (human hepatoblastoma) cells were assayed by the MTT{3-(4,5-dimethylthiazole-2-yl)-
2,5-diphenyltetrazolium bromide} colorimetric assay as previously described [23]. The cells for assay 
were cultured in  RPMI-1640 medium  supplemented  with  5% CO2  in  an  incubator at  37  ° C. The 
cytotoxicity assay depends on the binding of methylene blue to fixed monolayers of cells at pH 8.5, 
washing the monolayer, and releasing the dye by lowering the pH value. Samples and control standard 
drugs were prepared at a concentration of 1, 10, 40, and 100 μg/mL. After seeding 2880 cells/well in a 
96-well microplate for 3 h, 20 μL of sample or standard agent was placed in each well and incubated at 
37  ° C  for  3  days.  After  removing  the  medium  from  the  microplates,  the  cells  were  fixed  with  
10% formaldehyde in 0.9% saline for 30 min, then dyed with 1% (w/v) methylene blue in 0.01 M 
borate-buffer (100  μL/well) for 30 min. The 96-well plate was dipped into a 0.01 M borate-buffer 
solution four times in order to remove the dye. Then, 100 μL/well of EtOH-0.1 M HCl (1:1) was added 
as a dye eluting solvent, and the absorbance was measured on a microtiter plate reader (Dynatech,  
MR 7000) at a wavelength of 650 nm. The ED50 value was defined by a comparison with the untreated 
cells as the concentration of test sample resulting in 50% reduction of absorbance. Doxorubicin was 
used as a standard compound. 
3.9. Relaxation Assay of Topoisomerases I and II 
Topoisomerases I and II (topo I and II) assays were measured by assessing relaxation of supercoiled 
pBR322 plasmid DNA according to [24]. Using camptothecin (CPT) as topo I and etoposide (VP-16) 
as  topo  II  positive  controls,  test  samples  were  dissolved  in  5%  (v/v)  DMSO  and  then  diluted  to 
appropriate  concentrations.  In  summary,  topo  I  (TopoGen)  was  mixed  with  the  test  sample  and  
10 volume of assay buffer (100 mM Tris-HCl, 10 mM EDTA, 1.5 M NACl, 1.0% BSA, 1 M spermidine, 
and 50% glycerol), and then supercoiled DNA (pBR322) was added. In topo II assay, the mixture 
contained test sample and buffer including 50 mM Tris-HCl, 120 mM KCl, 10 mM MgCl2, 0.5 mM 
ATP, 0.5 mM dithiothreitol, 2 g BSA, pBR322 plasmid DNA (0.25 g), and 3U of topo II (TopoGen) 
in final volume of 20 L. After incubation of topo I or topo II mixture for 30 min at 37 ° C, 2 λ 10% 
SDS and 2.5 λ proteinase K were added for 1 h. The reaction mixtures were electrophoresed on a 2% 
agarose gel (50 V, 20 min; 100 V, 30 min; 110 V, 30 min) and stained with ethidium bromide. Finally, 
by a densitometer of ImageMaster
® (Fujifilm thermal imaging system, FTI-500), the gels were directly 
scanned and the area representing supercoiled DNA was calculated. Concentrations for 50% inhibition 
(IC50) were determined by interpolation from plots of topoisomerases I or II activity versus inhibitor 
concentration. Etoposide was used as a standard. Mar. Drugs 2011, 9  
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3.10. Molecular Modeling 
The three dimensional structures of DNA duplexes were obtained from the Brookhaven Protein 
Databank  (PDB  code  108d  or  264d).  The  3D  structures  of  compound  2  were  constructed  as  a 
protonated  form  and  were  assigned  Gasteiger-Huckel  partial  charges  using  Sybyl  7.0  (Tripos 
Associates; St. Louis, MO, USA) as previously described [25]. The AutoTors module was used to 
specify two rotatable bonds in 2 for AutoDock. The initial complex structure was then optimized by 
energy  minimization  with  the  Tripos  force  field,  employing  the  Powell  method  with  an  
energy-gradient-convergence  criterion  of  0.05  kcal/(mol  Ǻ)  and  a  distance-dependent  dielectric 
constant of 4 r. To carry out AutoDock simulations, a grid box was defined to enclose the interaction 
cavity with dimensions of 18.8 ×  18.8 ×  18.8 Ǻ. The grid maps for energy scoring were calculated with 
Autogrid  using  a  grid-point  spacing  of  0.375  Ǻ,  and  100  ×   76  ×   76  grid  points  for  108  d,  or  
70  ×   70  ×   110  grid  points  for  264  d.  200  independent  docking  runs  were  carried  out  using  the 
Lamarckian genetic algorithm (LGA) with a maximum number of 5,000,000 energy evaluations and a 
population of 50 randomly initiated individuals. The lowest-energy docked conformations proposed 
the energetically favorable binding modes of compound 2 to DNA. 
4. Conclusions 
In summary, a series of 1-substituted carbazolyl-1,2,3,4-tetrahydro- and carbazolyl-3,4-dihydro--
carboline analogs have been synthesized and evaluated as potential antitumor agents. Among them, 
compound 7 and 6 showed the most potent and selective activity against NCI-H661 and KB tumor 
cells, respectively. Compound 9 possessed most potent activity against DLD tumor cells. Compound 2 
exhibited most promising activity against KB, NCI-H661 and Hepa (or HepG2/A2) tumor cell lines. 
Inhibition of human DNA topoisomerase II revealed that compounds 3 and 4 are quite promising for 
further  development  of  enzyme  inhibitors.  The  SAR  revealed  that  there  was  a  lack  of  complete 
correlation between carbon numbers of the side chain and biological activities. However, the negative 
correlation was present between the alkyl side chain length in cytotoxicity tests. The optimal chain 
length is between 2 and 5 carbons. The optimal chain length for anti-topoisomerase II may be 3 and 5 
carbons. The DNA binding capacity, which favored minor groove binding, was thus influenced by the 
alkyl substitution on carbazole chromophore and proton donor on -carboline chromophore. On the 
basis of the SAR study, synthesis of analogs of lead compounds 2, 3, 6, 7 and 9, in order to search for 
more potent activity, is currently in progress. 
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